Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition.
Authors:Paul S,Hagenbeek TJ,Tremblay J,Kameswaran V,Ong C,Liu C,Guarnaccia AD,Mondo JA,Hsu PL,Kljavin NM,Czech B,Smola J,Nguyen DAH,Lacap JA,Pham TH,Liang Y,Blake RA,Gerosa L,Grimmer M,Xie S,Daniel B,Yao X,Dey A
Journal:Nature communications
PubMed ID:39966375
TEAD (transcriptional enhanced associate domain) transcription factors (TEAD1-4) serve as the primary effectors of the Hippo signaling pathway in various cancers. Targeted therapy leads to the emergence of resistance and the underlying mechanism of resistance to TEAD inhibition in cancers is less characterized. We uncover that upregulation of the AP-1 ... More